NEURACLE SCIENCE CO. LTD
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NEURACLE SCIENCE CO. LTD - overview
Established
2015
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Founded in 2015 and based in Seoul, South Korea, NEURACLE SCIENCE CO. LTD operates as a biopharmaceutical company that develops pharmaceutical treatments of neurodegenerative diseases. In June 2026, the company raised KRW 2 billion in pre-IPO funding from new investor BNH Investment. NEURACLE SCIENCE CO.
LTD develops treatments for severe neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and neurogenic bowel dysfunction. The company’s research includes candidates like NS101, an antibody currently in clinical development for Alzheimer’s disease and other neurodegenerative conditions, and NS200, which targets colonic motility disorders and neurogenic bowel dysfunction. Their development pipeline also features advanced antibody therapeutics, utilizing proprietary Fc Engineering to enhance drug efficacy. These solutions aim to improve nerve regeneration, synapse formation, and neural environment remodeling.
Current Investors
Shinhan Securities, NH Investment & Securities, BNK Asset Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Mental Health Services, Pharmaceutical Research & Development
Website
www.neuracles.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
NEURACLE SCIENCE CO. LTD - timeline of key events
NEURACLE SCIENCE CO. LTD - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 2,200,000,000 | - | 1,250,000,000 | 1,250,000,000 | - | - | - | - |
| % Revenue Growth (YoY) | - | (100.0%) | - | - | (100.0%) | - | - | - |
| EBITDA (USD) | (3,181,956,317) | (6,259,406,559) | (10,246,994,211) | (11,394,058,271) | (14,161,940,217) | - | - | - |
| Operating Income (USD) | (3,542,576,297) | (6,702,085,521) | (10,923,048,211) | (12,037,002,271) | (14,709,495,217) | - | - | - |
| Operating Margin | (161.0%) | - | (873.8%) | (963.0%) | - | - | - | - |
| % EBITDA Margin | (144.6%) | - | (819.8%) | (911.5%) | - | - | - | - |
| NET Income (USD) | (848,409,725) | (3,934,634,453) | (12,277,357,143) | (21,762,633,816) | (24,679,788,143) | - | - | - |
| % Net Margin | (38.6%) | - | (982.2%) | (1741.0%) | - | - | - | - |
NEURACLE SCIENCE CO. LTD - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.